ESOPHAGEAL CANCER DRUGS MARKET ANALYSIS

Name: Esophageal Cancer Drugs Market Size and Trends
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy
Keywords: Esophageal Cancer Drugs Market, Esophageal Cancer Drugs Market Report, Esophageal Cancer Drugs Industry Report, Esophageal Cancer Drugs Market Size, Esophageal Cancer Drugs Market Share, Esophageal Cancer Drugs Market Analysis, Esophageal Cancer Drugs Market Growth, Esophageal Cancer Drugs Market Trends, Esophageal Cancer Drugs Market Overview, Esophageal Cancer Drugs Market Forecast

Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2019 - 2027

Published In : Sep 2019
Code : CMI3036
Pages :166
Formats :
Excel and PDF
Industry : Pharmaceutical

Esophageal Cancer Drugs MarketSize and Trends

The global esophageal cancer drugs market size was valued at US$ 765.2 million in 2018 and is expected to witness a CAGR of 8.2% over the forecast period (2019 – 2027).

Increasing research & development and increasing prevalence of achalasia is expected to drive growth of the esophageal cancer drugs market

Increasing research and development and launches of novel products by key players are major factors that are expected to drive growth of the global esophageal cancer drugs market in the near future. Increasing research and development for new drug discovery for the treatment of esophageal cancer is expected to significantly drive growth of esophageal cancer drugs market size. For instance, in February 2019, researchers at Case Western Reserve University, U.S. found that by blocking two molecular pathways that send signals inside cancer cells could reduce esophageal adenocarcinoma (EAC), the most common esophageal malignancy in the U.S. These findings suggest JNK/TGF-beta-targeted therapy as a new treatment approach to treat esophageal cancer.

Global Esophageal Cancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027